SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Jesse Owens — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJesse Owens
Date of birth1913-09-12
IdentifiersMRN HR-ML042-SYN-TD; SSN (made up) 000-42-8319
Document date1979-09-30
AuthorClarence Whitfield-Arroyo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six weeks after left upper lobectomy: pathology and the plan from here. [S]

History of Present Illness

Mr. Owens returns six weeks after his thoracoscopic left upper lobectomy. He went home on the third day, needed no opioid after discharge, and stopped acetaminophen two weeks ago. Pathology shows only 0.7 cm of residual cancer with 6 percent viable tumor, a major pathologic response, with clear margins and no cancer in any of 16 lymph nodes. Dr. Halvorsen-Pierce reviewed the options with him last week. He walks 2 km a day and starts the pulmonary rehabilitation program next week. He gets mildly short of breath on two flights of stairs. He has not smoked for four months. He has had no thoughts of self-harm. [S]

ElementDetail
OperationThoracoscopic left upper lobectomy with lymph node dissection; three days in hospital; no complications
PathologyypT1a N0 (0 of 16), R0, major pathologic response (6 percent viable tumor)
TobaccoAbstinent four months on varenicline

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy returning; weight 74.6 kg; no fever
RespiratoryPositiveMild breathlessness on two flights of stairs; no cough or sputum
MusculoskeletalPositiveMild aching at the port sites
EndocrineNegativeNo cold intolerance or constipation
NeurologicalNegativeNo numbness or tingling
PsychiatricNegativeRelieved and hopeful; PHQ-2 0

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 80.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7Oral route1979-05-26 to 1979-06-01completedS
Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse1 mg twice daily after foodOral route1979-06-02activeS
Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial)Day 1 every 21 days for three cyclesIntravenous route1979-06-03 to 1979-07-15completedS
Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route1979-06-03 to 1979-07-15completedS
Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route1979-06-03 to 1979-07-15completedS
Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the lastOne tablet dailyOral route1979-05-26 to 1979-08-05completedS
Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed)1000 mcg once; a second dose was not due before pemetrexed endedIntramuscular route1979-05-26 to 1979-05-26completedS
Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose4 mg twice daily for three days around each cycleOral route1979-06-02 to 1979-07-16completedS
Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy8 mg every 8 hours as neededOral route1979-06-03 to 1979-07-31completedS
Acetaminophen 500 mg oral tablet, two tablets every 8 hours as needed for pain after surgery1000 mg every 8 hours as neededOral route1979-08-22 to 1979-09-15completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1979-09-30Body height178cmS
1979-09-30Body weight74.6kgS
1979-09-30Body mass index (BMI) [Ratio]23.5kg/m2S
1979-09-30Systolic blood pressure122mm[Hg]S
1979-09-30Diastolic blood pressure76mm[Hg]S
1979-09-30Heart rate76/minS
1979-09-30Respiratory rate16/minS
1979-09-30Body temperature36.6CelS
1979-09-30Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1979-09-30Hemoglobin [Mass/volume] in Blood13.4g/dL13.5-17.5 g/dLLowS
1979-09-30Leukocytes [#/volume] in Blood by Automated count710*3/uL4-11 10*3/uLNormalS
1979-09-30Neutrophils [#/volume] in Blood by Automated count4.310*3/uL1.5-7.7 10*3/uLNormalS
1979-09-30Platelets [#/volume] in Blood by Automated count24610*3/uL150-400 10*3/uLNormalS
1979-09-30Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.7-1.3 mg/dLNormalS
1979-09-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1979-09-30Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
1979-09-30Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
1979-09-30Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-48 U/LNormalS
1979-09-30Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1979-09-30Thyrotropin [Units/volume] in Serum or Plasma4.6m[IU]/L0.4-4 mIU/LHighS
1979-09-30Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
1979-09-30Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 1979-09-30; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 74.6 kg; blood pressure 122/76, pulse 76; oxygen saturation 96 percent
RespiratoryBreath sounds slightly reduced at the left apex; no crackles; port-site incisions healed
CardiovascularRegular rhythm; no edema
Lymph nodesNo supraclavicular nodes

Problems

ProblemClinical statusVerificationCodeProvenance
Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review bookedresolvedconfirmed R91.1S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit.
Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alterationactiveconfirmed C34.12S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable.
Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicineresolvedconfirmed F17.210S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission.
Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness; not a historical claim.
After thoracoscopic left upper lobectomy with mediastinal and hilar lymph node dissection: ypT1a N0 (0 of 16 nodes), R0, major pathologic response (6 percent residual viable tumor)activeconfirmed Z90.2S — Synthetic consequence of the synthetic operation.
Nicotine dependence, cigarettes, in early remission: no cigarettes since day 1 of cycle 1, about four months, on vareniclineactiveconfirmed F17.211S — Synthetic modern entry linked to his documented smoking.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with neutrophils and plateletsAfter treatment, as indicatedCompleted todayHemoglobin 13.4 (recovering), white cells 7.0, neutrophils 4.3, platelets 246
LaboratoryThyroid, liver, kidney and glucose tests after immunotherapyAfter the last dose and for symptoms; thyroid every 6 to 12 weeks for a year after a riseCompleted todayTSH 4.6 (slightly high) with free T4 1.1; ALT 24, AST 22, bilirubin 0.5; creatinine 1.0, eGFR 84; glucose 92
ImagingSurveillance chest CTEvery six months for two to three years after curative treatment, then yearly low-dose CTDueFirst surveillance CT booked for six months after surgery
ImagingRoutine brain MRI, PET-CT and circulating tumor markers for surveillanceNot recommended in stage I to IIINot indicatedNot used without symptoms
Self-managementPulmonary rehabilitation after lung resection6 to 12 week program after surgeryReferredStarts next week
Self-managementTobacco use and cessation treatmentEvery visitCompleted todayAbstinent four months; varenicline to 24 weeks
SurveyDistress and depression screeningEvery visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitionsCompleted todayPHQ-2 0
ExaminationDyspnea and cough assessmentEvery visitCompleted todayMild breathlessness on two flights; no cough
ExaminationPeripheral neuropathy after platinumEvery visit during and after platinum therapyCompleted todayNone
SurveyCancer-related fatigueEvery visitCompleted todayMild, improving
Self-managementImmunizations after treatmentPer the adult scheduleDueInfluenza, COVID-19, RSV and zoster vaccines at the wellness visit in three weeks

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Schneider BJ, et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Summary. JCO Oncol Pract 2020;16(2):83-86 (PMID 32045555) (2020); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)

Follow-up: Pulmonary rehabilitation from next week. Annual wellness visit in three weeks. Surveillance CT in about six months. Call for new cough, hemoptysis, bone pain, headache or weight loss. Next scheduled visit 1979-10-21: subsequent annual wellness visit. [S]